Transcenta Holding Limited has announced updated efficacy data from the phase I/II Transtar102 trial evaluating osemitamab in combination with nivolumab and CAPOX as a first-line treatment for gastric or gastroesophageal junction (G/GEJ) cancer. The findings were presented in a poster session at the ESMO Asia Congress 2025 in Singapore. In a subgroup of 26 patients with high CLDN18.2 expression (≥40%, ≥2+), the median progression-free survival $(PFS)$ was 16.6 months, the objective response rate $(ORR)$ was 68%, and the median duration of response (DoR) was 18 months at a median follow-up of 25.8 months. The results indicated consistent treatment benefit of osemitamab regardless of PD-L1 expression levels.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcenta Holding Limited published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251205-11945375), on December 04, 2025, and is solely responsible for the information contained therein.
